Literature DB >> 2062812

Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

A V Boddy1, G W Elmer, L V McFarland, R H Levy.   

Abstract

Saccharomyces boulardii (SB) is a yeast that is used for the prevention and treatment of antibiotic-associated diarrhea and for the treatment of pseudomembranous colitis. Since SB will most commonly be used when the bacterial flora of the gastrointestinal tract have been disrupted by antibiotic treatment, the influence of different antibiotics on the kinetics and recovery of SB in feces was investigated in rats. Following a single oral dose, SB concentrations in feces were measured for periods of 1 to 6 days. Although SB is eliminated exclusively in the feces, less than 3% of the dose is recovered as viable yeast. When rats were treated with neomycin, which is active against gram-negative aerobic bacteria but not against anaerobes, no change was observed in recovery of SB when compared with recovery from untreated rats. Also, there was no change in the rate at which SB concentrations declined in feces. In contrast, treatment with clindamycin and the broad-spectrum antibiotic ampicillin, which are active against anaerobes, produced an increase in the recovery of SB of up to seven times that of controls and slowed the rate of decline of SB concentration in the feces. This antibiotic effect on SB disposition was also found when SB was administered in multiple doses. An eightfold increase in the steady-state output of SB was observed from ampicillin-treated animals. Analysis of the recovery and kinetic data showed that the primary effect of these antibiotics was to reduce the destruction of SB, probably in the cecum and colon.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062812     DOI: 10.1023/a:1015822605815

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Disposition kinetics of Saccharomyces boulardii in man and rat.

Authors:  H Blehaut; J Massot; G W Elmer; R H Levy
Journal:  Biopharm Drug Dispos       Date:  1989 Jul-Aug       Impact factor: 1.627

2.  On the mathematics of digesta flow kinetics.

Authors:  J France; J H Thornley; M S Dhanoa; R C Siddons
Journal:  J Theor Biol       Date:  1985-04-21       Impact factor: 2.691

3.  Colonization resistance of the digestive tract in conventional and antibiotic-treated mice.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1971-09

4.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; G Elmer; J Chinn
Journal:  Am J Gastroenterol       Date:  1989-10       Impact factor: 10.864

Review 5.  Review of Clostridium difficile-associated diseases.

Authors:  L V McFarland; W E Stamm
Journal:  Am J Infect Control       Date:  1986-06       Impact factor: 2.918

6.  Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster.

Authors:  J Massot; O Sanchez; R Couchy; J Astoin; A L Parodi
Journal:  Arzneimittelforschung       Date:  1984

7.  [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice].

Authors:  R Ducluzeau; M Bensaada
Journal:  Ann Microbiol (Paris)       Date:  1982 Nov-Dec

8.  Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery.

Authors:  L Kager; L Liljeqvist; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

9.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.

Authors:  C M Surawicz; G W Elmer; P Speelman; L V McFarland; J Chinn; G van Belle
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

10.  Selection among nonlinear models for rate of passage studies in ruminants.

Authors:  R A Quiroz; K R Pond; E A Tolley; W L Johnson
Journal:  J Anim Sci       Date:  1988-11       Impact factor: 3.159

View more
  7 in total

1.  Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats.

Authors:  J P Buts; N De Keyser; S Marandi; D Hermans; E M Sokal; Y H Chae; L Lambotte; H Chanteux; P M Tulkens
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 2.  Microecologic approaches for traveler's diarrhea, antibiotic-associated diarrhea, and acute pediatric diarrhea.

Authors:  L V McFarland
Journal:  Curr Gastroenterol Rep       Date:  1999-08

3.  Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Authors:  S M Klein; G W Elmer; L V McFarland; C M Surawicz; R H Levy
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

4.  Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats.

Authors:  Philippe Girard; Yannick Pansart; Ingrid Lorette; Jean-Marie Gillardin
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

5.  Recombinant Saccharomyces cerevisiae strain expressing a model cytochrome P450 in the rat digestive environment: viability and bioconversion activity.

Authors:  G Garrait; J F Jarrige; S Blanquet; E Beyssac; M Alric
Journal:  Appl Environ Microbiol       Date:  2007-04-06       Impact factor: 4.792

6.  Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.

Authors:  Lauren E Hudson; Milo B Fasken; Courtney D McDermott; Shonna M McBride; Emily G Kuiper; David B Guiliano; Anita H Corbett; Tracey J Lamb
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

7.  S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.

Authors:  Vincent Cascio; Daniel Gittings; Kristen Merloni; Matthew Hurton; David Laprade; Nicanor Austriaco
Journal:  BMC Microbiol       Date:  2013-02-13       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.